VEGFR2/KDR/Flk-1 Antibody (89106R) [Unconjugated]

HUVEC human umbilical vein endothelial cells were stained with Mouse Anti-Human VEGFR2/KDR/Flk-1 Monoclonal Antibody (Catalog # MAB3572R, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). View our protocol for Staining Membrane-associated Proteins.

Recombinant Human VEGFR2/KDR Fc Chimera (Catalog # 357-KD) inhibits Recombinant Human VEGF165 (Catalog # 293-VE) induced proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Inhibition of Recombinant Human VEGF165 (10 ng/mL) activity elicited by Recombinant Human VEGFR2/KDR Fc Chimera (50 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human VEGFR2/KDR Monoclonal Antibody (Catalog # MAB3572R). The ND50 is typically 10-50 ng/mL.

• Reactivity: Hu
• Applications: Flow, B/N, CyTOF-ready
• Clone: 89106R
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

VEGFR2/KDR/Flk-1 Antibody (89106R) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human VEGFR2/KDR/Flk-1
  Ala20-Glu764
  Accession # P35968
• Specificity: Detects human VEGFR2/KDR/Flk-1 in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells
  • Neutralization

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for VEGFR2/KDR/Flk-1 Antibody (89106R) [Unconjugated]

• CD309 antigen
• CD309
• EC 2.7.10
• EC 2.7.10.1
• Fetal liver kinase 1
• fetal liver kinase-1
• Flk1
• Flk-1
• FLK1tyrosine kinase growth factor receptor
• KDR
• kinase insert domain receptor (a type III receptor tyrosine kinase)
• Kinase insert domain receptor
• KRD1
• Ly73
• Protein-tyrosine kinase receptor flk-1
• soluble VEGFR2
• vascular endothelial growth factor receptor 2
• VEGF R2
• VEGFR
• VEGFR2
• VEGFR-2

Background

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. Mature VEGFR2 is composed of a 745 aa extracellular domain, a 25 aa transmembrane domain and a 567 aa cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P35968()